Stock STIM NEURONETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Neuronetics, Inc. Stock

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX
Other stock markets
 03:04:04 2024-12-11 pm EST 		5-day change 1st Jan Change
1.200 USD +5.26% Intraday chart for Neuronetics, Inc. +1.70% -58.79%
Dec. 09 Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. CI
Nov. 12 Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024

Valuation: Neuronetics, Inc.

Capitalization 34.6M 32.93M 30.52M 27.14M 49M 2.94B 54.3M 380M 140M 1.21B 130M 127M 5.26B P/E ratio 2024 *
-0.9x
P/E ratio 2025 * -1.7x
Enterprise value 34.6M 32.93M 30.52M 27.14M 49M 2.94B 54.3M 380M 140M 1.21B 130M 127M 5.26B EV / Sales 2024 *
0.48x
EV / Sales 2025 * 0.45x
Free-Float
88.91%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Neuronetics, Inc.

Dynamic Chart

Latest news: Neuronetics, Inc.

Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec. 08 CI
Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024 Nov. 12
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $18.5M Nov. 12 MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 12 CI
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov. 12 CI
Neuronetics, Greenbrook Receive Interim Order for Special Meeting of Shareholders for Greenbrook Oct. 04 MT
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults Sep. 19 CI
William Blair Downgrades Neuronetics to Market Perform From Outperform Aug. 13 MT
Neuronetics Shares Slump as Q2 Results Fall Below Estimates; Merger Announcement Aug. 12 MT
Neuronetics, Inc., Q2 2024 Earnings Call, Aug 12, 2024 Aug. 12
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 12 CI
Earnings Flash (STIM) NEURONETICS Reports Q2 Revenue $16.5M, vs. Street Est of $18.7M Aug. 12 MT
Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024 Aug. 12 CI
More news

Last Transcript: Neuronetics, Inc.

Logo Neuronetics, Inc.
Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024
Nov. 12
More transcripts

Analysts' recommendations: Neuronetics, Inc.

William Blair Downgrades Neuronetics to Market Perform From Outperform Aug. 13 MT
William Blair Upgrades Neuronetics to Outperform From Market Perform May. 14 MT
Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating 23-03-08 MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating 22-01-03 MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating 21-10-14 MT
More recommendations

Press Releases: Neuronetics, Inc.

Neuronetics : and Greenbrook TMS Announce Closing of Transaction Form 8 K Dec. 10 PU
Neuronetics and Greenbrook TMS Announce Closing of Transaction Dec. 10 AQ
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference Nov. 20 AQ
Neuronetics Reports Inducement Grant under Nasdaq Listing Rule 5635(4) Nov. 13 AQ
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Nov. 12 AQ
More press releases

Quotes and Performance

1 day-0.87%
1 week-0.87%
Current month+14.00%
1 month-2.56%
3 months+46.15%
6 months-43.56%
Current year-60.69%
More quotes

Course Extremes

1 week
1.00
Extreme 1.001
1.34
1 month
0.52
Extreme 0.52
1.34
Current year
0.52
Extreme 0.52
5.07
1 year
0.52
Extreme 0.52
5.07
3 years
0.52
Extreme 0.52
6.95
5 years
0.52
Extreme 0.52
22.43
10 years
0.52
Extreme 0.52
39.39
More quotes

Managers and Directors: Neuronetics, Inc.

Director TitleAgeSince
Keith Sullivan CEO
 Chief Executive Officer 65 2020-07-13
Stephen Furlong DFI
 Director of Finance/CFO 60 2019-07-21
Cory Anderson CTO
 Chief Tech/Sci/R&D Officer - 2021-02-28
Manager TitleAgeSince
Glenn Muir BRD
 Director/Board Member 65 2017-06-30
Sheryl Conley BRD
 Director/Board Member 63 2019-09-30
Keith Sullivan BRD
 Director/Board Member 65 2020-07-13
More insiders

ETFs: Neuronetics, Inc.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD US TOTAL MARKET SHARES INDEX ETF ETF Vanguard US Total Market Shares Index ETF
0.00% 293,477 M€ +34.97% -
More ETFs: Neuronetics, Inc.

Other Advanced Medical Equipment & Technology

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
NEURONETICS, INC. Stock Neuronetics, Inc.
-0.87%-0.87%-37.70%-74.32%34.6M
THERMO FISHER SCIENTIFIC INC. Stock Thermo Fisher Scientific Inc.
-0.26%+0.27%+9.41%-16.60%205B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
-0.14%-0.67%+73.34%+55.99%192B
DANAHER CORPORATION Stock Danaher Corporation
-0.67%-2.71%+7.75%-26.19%169B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+1.67%-0.30%+64.15%+119.09%133B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.02%+3.63%+2.60%-19.31%62.94B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+1.20%+0.87%-11.16%-29.04%43.85B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+3.51%+4.54%+6.09%-39.77%43.29B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-1.44%+1.90%+11.58%-9.17%40.48B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+0.56%-0.25%+20.20% - 37.63B
Average +0.29%+0.72%+14.63%-4.37% 92.7B
Weighted average by Cap. +0.07%+0.06%+29.11%+15.90%
See all sector performances

Financials

2024 *2025 *
Net sales 71.36M 67.92M 62.94M 55.98M 101M 6.06B 112M 784M 289M 2.49B 268M 262M 10.85B 76.99M 73.28M 67.91M 60.4M 109M 6.53B 121M 846M 312M 2.68B 289M 283M 11.71B
Net income -38.94M -37.07M -34.35M -30.55M -55.15M -3.3B -61.12M -428M -158M -1.36B -146M -143M -5.92B -23.88M -22.73M -21.07M -18.74M -33.82M -2.03B -37.48M -262M -96.83M -832M -89.66M -87.73M -3.63B
Net Debt - -
More financial data * Estimated data

Company Profile

Logo Neuronetics, Inc.
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Employees
201
Sector
Advanced Medical Equipment & Technology
Calendar
2025-03-10 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
24-12-11 1.200 $ +5.26% 76,096
24-12-10 1.140 $ -0.87% 166,984
24-12-09 1.150 $ -9.45% 222,815
24-12-06 1.270 $ +6.72% 523,587
24-12-05 1.190 $ +1.28% 85,530

Delayed Quote Nasdaq, December 10, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart NEURONETICS-INC More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
C-
surperformance-ratings-light-chart NEURONETICS-INCMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.140USD
Average target price
2.667USD
Spread / Average Target
+133.92%
Consensus
Profit revisions
estimates-change-chart NEURONETICS-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart NEURONETICS-INC Company calendar
  1. Stock Market
  2. Equities
  3. STIM Stock